Published in Ther Deliv on February 01, 2015
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol (1995) 9.02
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Heterosexual anal intercourse increases risk of HIV infection among young South African men. AIDS (2006) 2.34
The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol (2000) 2.26
PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release (2001) 2.15
Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin Investig Drugs (2002) 2.06
Formulation and in vitro, in vivo evaluation of extended- release matrix tablet of zidovudine: influence of combination of hydrophilic and hydrophobic matrix formers. AAPS PharmSciTech (2006) 1.64
Skin permeation: the years of enlightenment. Int J Pharm (2005) 1.59
Topical microbicides for disease prevention: status and challenges. Clin Infect Dis (2003) 1.58
Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res Hum Retroviruses (1994) 1.33
Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm (2006) 1.32
Challenges and opportunities in dermal/transdermal delivery. Ther Deliv (2010) 1.32
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother (2011) 1.25
An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med (2012) 1.23
Percutaneous penetration enhancers: an overview. Skin Pharmacol Physiol (2007) 1.22
Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci (2008) 1.20
Transdermal delivery of zidovudine (AZT): the effects of vehicles, enhancers, and polymer membranes on permeation across cadaver pig skin. AAPS PharmSciTech (2004) 1.18
Effect of L-menthol and 1,8-cineole on phase behavior and molecular organization of SC lipids and skin permeation of zidovudine. J Control Release (2005) 1.18
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16
A comparison between povidone-ethylcellulose and povidone-eudragit transdermal dexamethasone matrix patches based on in vitro skin permeation. Eur J Pharm Biopharm (2005) 1.16
HIV therapeutics. Science (1996) 1.14
Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochim Biophys Acta (2009) 1.13
SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob Agents Chemother (2001) 1.10
Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One (2014) 1.09
Single-layer transdermal film containing lidocaine: modulation of drug release. Eur J Pharm Biopharm (2006) 1.07
Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int J Pharm (2007) 1.07
Transdermal drug delivery: PAST, PRESENT, FUTURE. Mol Interv (2004) 1.07
Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res (2003) 1.06
Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob Agents Chemother (1997) 1.03
Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm (2008) 1.01
Permeability of tritiated water through human cervical and vaginal tissue. J Pharm Sci (2004) 1.00
Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation. J Pharm Sci (1996) 0.93
Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides. Antimicrob Agents Chemother (2011) 0.92
Hydrogel-forming and dissolving microneedles for enhanced delivery of photosensitizers and precursors. Photochem Photobiol (2013) 0.91
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. Clin Diagn Lab Immunol (2002) 0.91
Design and evaluation of transdermal drug delivery system for curcumin as an anti-inflammatory drug. Drug Dev Ind Pharm (2009) 0.88
Status of surfactants as penetration enhancers in transdermal drug delivery. J Pharm Bioallied Sci (2012) 0.88
Electrically-assisted transdermal drug delivery. Pharm Res (1997) 0.88
Current advances in the fabrication of microneedles for transdermal delivery. J Control Release (2014) 0.87
Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes. Nanomedicine (2010) 0.87
Studies on transdermal delivery enhancement of zidovudine. AAPS PharmSciTech (2009) 0.86
Synthesis of methoxypoly(ethylene glycol) carbonate prodrugs of zidovudine and penetration through human skin in vitro. J Pharm Pharmacol (2009) 0.85
Enhanced transdermal delivery of AZT (Zidovudine) using iontophoresis and penetration enhancer. J Control Release (1998) 0.84
Microneedle-based drug delivery systems for transdermal route. Curr Drug Targets (2014) 0.84
Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy. Expert Opin Investig Drugs (2004) 0.84
New epidermal model for dermal irritancy testing. Toxicol In Vitro (1994) 0.83
Mutual hairless rat skin permeation-enhancing effect of ethanol/water system and oleic acid. J Pharm Sci (1996) 0.82
Fabrication and evaluation of polymeric films for transdermal delivery of pinacidil. Pharmazie (2004) 0.81
Temoporfin-loaded liposomal gels: viscoelastic properties and in vitro skin penetration. Int J Pharm (2009) 0.81
Evaluation of mathematical models describing drug release from estradiol transdermal systems. Drug Dev Ind Pharm (2003) 0.81
PEGylated elastic liposomal formulation for lymphatic targeting of zidovudine. Curr Drug Deliv (2008) 0.81
Rapidly dissolvable microneedle patches for transdermal delivery of exenatide. Pharm Res (2014) 0.80
Parenteral administration of progestins for hormonal replacement therapy. Eur J Contracept Reprod Health Care (2009) 0.80
Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 1. Stability studies for hairless rat skin permeation. J Pharm Sci (1995) 0.79
Iontophoresis: a potential emergence of a transdermal drug delivery system. Sci Pharm (2011) 0.79
Lecithin-based nanostructured gels for skin delivery: an update on state of art and recent applications. J Control Release (2014) 0.79
A novel skin penetration enhancer: evaluation by membrane diffusion and confocal microscopy. J Pharm Pharm Sci (2000) 0.78
Novel strategies for effective transdermal drug delivery: a review. Crit Rev Ther Drug Carrier Syst (2014) 0.78
Transdermal delivery of zalcitabine: in vitro skin permeation study. AIDS (1995) 0.78
Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet tablet containing a single excipient. J Pharm Sci (2013) 0.78
In vitro and ex vivo evaluations on transdermal delivery of the HIV inhibitor IQP-0410. PLoS One (2013) 0.77
Preparation and evaluation of dl-praeruptorin A microemulsion based hydrogel for dermal delivery. Drug Deliv (2014) 0.76
Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease. Issues Emerg Health Technol (2008) 0.76
Percutaneous absorption of 2',3'-dideoxyinosine in rats. Pharm Res (1994) 0.76
Synthesis and in vitro transdermal penetration of methoxypoly(ethylene glycol) carbonate and carbamate derivatives of lamivudine (3TC). Med Chem (2010) 0.75
In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses (2005) 3.89
Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem (2004) 2.07
Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems. J Med Chem (2007) 1.76
Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother (2008) 1.68
Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis (2007) 1.40
A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry (2003) 1.37
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother (2006) 1.37
Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob Agents Chemother (2003) 1.29
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother (2011) 1.25
Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins. Antimicrob Agents Chemother (2008) 1.20
Novel targets for HIV therapy. Antiviral Res (2008) 1.15
Gap junction turnover is achieved by the internalization of small endocytic double-membrane vesicles. Mol Biol Cell (2009) 1.11
Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm Res (2012) 1.10
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. Antimicrob Agents Chemother (2010) 1.08
Optimization of unique, uncharged thioesters as inhibitors of HIV replication. Bioorg Med Chem (2004) 1.02
Green-to-red photoconvertible fluorescent proteins: tracking cell and protein dynamics on standard wide-field mercury arc-based microscopes. BMC Cell Biol (2010) 1.02
Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J Pharm Sci (2012) 1.01
"Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav (2014) 1.00
Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings. Bioorg Med Chem (2006) 0.99
Susceptibilities of simian immunodeficiency virus to protease inhibitors. Antimicrob Agents Chemother (2003) 0.95
Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur J Med Chem (2008) 0.95
Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. Retrovirology (2011) 0.95
Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem (2005) 0.95
HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. J Virol (2014) 0.94
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability. J Med Chem (2007) 0.93
Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention. Antiviral Res (2012) 0.93
Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides. Antimicrob Agents Chemother (2011) 0.92
Synthesis of alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors with non-identical aromatic rings. Bioorg Med Chem (2002) 0.91
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob Agents Chemother (2010) 0.90
Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay. Antimicrob Agents Chemother (2008) 0.90
Replacement of the metabolically labile methyl esters in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors with isoxazolone, isoxazole, oxazolone, or cyano substituents. J Med Chem (2006) 0.89
Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme. J Med Chem (2007) 0.89
Binaphthyl-based dicationic peptoids with therapeutic potential. Angew Chem Int Ed Engl (2010) 0.88
Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development. Protein Expr Purif (2005) 0.84
CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants. Retrovirology (2013) 0.84
Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Retrovirology (2013) 0.84
Multivalent binding oligomers inhibit HIV Tat-TAR interaction critical for viral replication. Bioorg Med Chem Lett (2009) 0.84
The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets. Mol Biol Int (2012) 0.83
Antiviral activity of hop constituents against a series of DNA and RNA viruses. Antiviral Res (2004) 0.82
Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles. Int J Pharm (2011) 0.82
Total synthesis of anibamine, a novel natural product as a chemokine receptor CCR5 antagonist. Org Lett (2007) 0.81
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef. Antimicrob Agents Chemother (2010) 0.81
Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase. J Med Chem (2009) 0.79
Antiviral interactions of combinations of highly potent 2,4(1H,3H)-pyrimidinedione congeners and other anti-HIV agents. Antiviral Res (2011) 0.79
Antiviral amphipathic oligo- and polyribonucleotides: analogue development and biological studies. J Med Chem (2003) 0.78
Potent inhibition of HIV-1 entry by (s4dU)35. Virology (2005) 0.78
Evolution of an attenuated HIV-1 isolate in an elite suppressor. AIDS Res Hum Retroviruses (2013) 0.77
In vitro and ex vivo evaluations on transdermal delivery of the HIV inhibitor IQP-0410. PLoS One (2013) 0.77
Synthesis of substituted diarylmethylenepiperidines (DAMPs), a novel class of anti-HIV agents. Bioorg Med Chem (2002) 0.77
Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1. Mol Biol Int (2012) 0.77
1-Benzyl derivatives of 5-(arylamino)uracils as anti-HIV-1 and anti-EBV agents. Bioorg Med Chem (2010) 0.75
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors. Bioorg Med Chem Lett (2007) 0.75
Inhibition of tubulin polymerization by select alkenyldiarylmethanes. Bioorg Med Chem Lett (2007) 0.75
Selection and characterization of viruses resistant to the dual acting pyrimidinedione entry and non-nucleoside reverse transcriptase inhibitor IQP-0410. Antiviral Res (2013) 0.75
An unusual "senseless" 2',5'-oligoribonucleotide with potent anti-HIV activity. Nucleosides Nucleotides Nucleic Acids (2004) 0.75
"Senseless" antiviral polyribonucleotides: poly (1-propargylinosinic acid). Nucleosides Nucleotides Nucleic Acids (2002) 0.75
Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett (2012) 0.75